Loading…
Strategia Project Management, Inc. was cited for selling an unapproved non-alcohol-based topical antiseptic product intended to mitigate, prevent, treat, diagnose, or cure COVID-19 and other serious infections, violating section 505(a) of the Federal Food, Drug, and Cosmetic Act by marketing an unapproved new drug. The company also misbranded the product in violation of sections 502(a) and (ee) of the FD&C Act and unlawfully introduced it into interstate commerce through its website (microsure.com) and social media platforms. The enforcement action was undertaken during the COVID-19 public health emergency, when the FDA prioritized urgent measures to protect consumers from unauthorized COVID-19 treatment products.